Zobrazeno 1 - 4
of 4
pro vyhledávání: '"AK Smol'yaninova"'
Autor:
E E Zvonkov, ER Moskalets, SA Tatarnikova, I. E. Kostina, AS Bogolyubskaya, GA Yatsyk, N G Gabeeva, DS Badmadzhapova, AK Smol’yaninova, EG Gemdzhian
Publikováno v:
Clinical oncohematology. 13:33-49
Background. Primary bone lymphoma (PBL) is a rare malignant tumor. Initial examination aimed at detecting all primary lesions is an indispensable prerequisite for the choice of optimal antitumor treatment. Standard methods of diagnosis (X-ray, CT, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9964e4f729264bbd055b655e09a9d07a
https://doi.org/10.21320/2500-2139-2020-13-1-33-49
https://doi.org/10.21320/2500-2139-2020-13-1-33-49
Autor:
AK Smol’yaninova, ER Moskalets, GA Yatsyk, IE Kostina, AS Bogolyubskaya, NG Gabeeva, EG Gemdzhian, SA Tatarnikova, DS Badmadzhapova, EE Zvonkov
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 13, Iss 1, Pp 33-49 (2019)
Background. Primary bone lymphoma (PBL) is a rare malignant tumor. Initial examination aimed at detecting all primary lesions is an indispensable prerequisite for the choice of optimal antitumor treatment. Standard methods of diagnosis (X-ray, CT, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::12f03cce6bbe455f9224c8d3ebe0de2d
https://doaj.org/article/b28ee3e17ade42139458e313db7b2687
https://doaj.org/article/b28ee3e17ade42139458e313db7b2687
Autor:
DS Badmadzhapova, Alla M. Kovrigina, E E Zvonkov, AK Smol’yaninova, Mamonov Ve, EG Gemdzhian, SA Tatarnikova, N G Gabeeva, LG Gorenkova
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 12, Iss 3, Pp 247-262 (2019)
Background. Primary bone lymphomas (PBL) are rare extranodal lymphomas. In more than 90 % of cases they are reported as diffuse large B-cell lymphomas (DLBCL). At local (IE) stage of PBL the standard R-CHOP immunotherapy demonstrates efficacy over 90
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f267bdace776cf35953600136b8a8242
https://doaj.org/article/b647d733631144d39f0e06e740827c45
https://doaj.org/article/b647d733631144d39f0e06e740827c45
Autor:
E E Zvonkov, EG Gemdzhyan, Alla M. Kovrigina, N G Gabeeva, SA Tatarnikova, AK Smol’yaninova, A.V. Belyaeva
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 11, Iss 4, Pp 338-348 (2018)
Background. MALT-lymphoma is usually characterized with an indolent course. The factors underlying the effectiveness of the standard chemotherapy in patients with MALT-lymphomas include MALT-IPI risk group and a high SUVmax according to the results o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c300959e2d192998bd0713516a324ebd
http://bloodjournal.ru/wp-content/uploads/2018/09/8-1.pdf
http://bloodjournal.ru/wp-content/uploads/2018/09/8-1.pdf